CN-122005587-A - Application of ginsenoside Rg4 as unique active ingredient in preparation of medicine for improving male delayed hypogonadism

CN122005587ACN 122005587 ACN122005587 ACN 122005587ACN-122005587-A

Abstract

The application of ginsenoside Rg4 as the only active ingredient in preparing the medicine for improving male delayed hypogonadism belongs to the field of biological medicine. The invention firstly defines the action mechanism of improving LOH by Rg4, wherein Rg4 can specifically up-regulate mRNA expression quantity of StAR and StARD7 in testis tissues, promote transfer of cholesterol to mitochondrial inner membranes of testis Leydig cells from transcription level, promote mRNA expression quantity of P450scc and 3 beta-HSD in testis tissues by promoting efficient transfer of cholesterol, enhance conversion of cholesterol to pregnenolone and subsequent catalytic synthesis of steroid, promote endogenous testosterone synthesis capability, and Rg4 can restore negative feedback regulation function of HPG axis, regulate secretion of pituitary LH and FSH to physiological steady state and avoid abnormal fluctuation of hormone level. The invention fills the technical blank of Rg4 in the field of LOH gene regulation.

Inventors

YANG XIQUAN

Assignees

通化承诚药业有限公司

Dates

Publication Date: 20260512
Application Date: 20260414

Claims (4)

1. The application of ginsenoside Rg4 as the only active ingredient in preparing the medicine for improving male delayed hypogonadism is provided.
2. Use of ginsenoside Rg4 according to claim 1 as sole active ingredient for the preparation of a medicament for improving male delayed hypogonadism, wherein the functions of ginsenoside Rg4 comprise: (1) Increasing serum total testosterone and free testosterone levels; (2) Inhibiting abnormal elevation of levels of xanthogen and follicle stimulating hormone in serum; (3) Targeting the transcriptional level of a core key gene that regulates testosterone synthesis in testicular Leydig cells; (4) Promote the transportation and transformation of cholesterol; (5) Promoting endogenous testosterone synthesis; (6) The hormone secretion homeostasis of the HPG axis is regulated.
3. Use of ginsenoside Rg4 according to claim 1 as sole active ingredient for the preparation of a medicament for improving male delayed hypogonadism, characterized in that the preparation method of ginsenoside Rg4 is as follows: (1) Preparing a pediococcus acidilactici TH903 bacterial suspension; Activating Pediococcus acidilactici TH903, inoculating to a liquid MRS culture medium, standing for culture, centrifuging, collecting bacterial precipitate, suspending with sterilized distilled water, and regulating viable count to obtain Pediococcus acidilactici TH903 bacterial suspension; (2) Preparing ginseng berry extract; weighing ginseng berry, adding deionized water, extracting under reflux, filtering, mixing filtrates, and concentrating under reduced pressure to obtain ginseng berry extract; (3) Fermenting and converting; adding glucose into the ginseng berry extract, adding hydrochloric acid to adjust pH, inoculating Pediococcus acidilactici TH903 bacterial suspension, and standing for culturing to obtain fermentation product; (4) Concentrating the obtained fermentation product under reduced pressure, and vacuum freeze-drying to obtain dry powder; (5) And identifying ginsenoside Rg4 contained in the dry powder by using a high performance liquid chromatography method.
4. The use of ginsenoside Rg4 as the sole active ingredient in the preparation of a medicament for improving male delayed hypogonadism according to claim 3, wherein pediococcus acidilactici TH903 is preserved in China center for type culture collection with the preservation number of CCTCC NO: M20252155 at the year 09 month 29 of 2025.

Description

Application of ginsenoside Rg4 as unique active ingredient in preparation of medicine for improving male delayed hypogonadism Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of ginsenoside Rg4 serving as a unique active ingredient in preparation of a medicament for improving male delayed hypogonadism. Background Male delayed hypogonadism (LOH) is a syndrome of middle-aged and elderly men caused by testis Leydig cell dysfunction, and has core pathology of reduced endogenous testosterone synthesis, hypothalamus-pituitary-gonad (HPG) shaft dysfunction, significantly down-regulated mRNA expression level of testosterone synthesis core key genes of testis Leydig cells, clinically manifested as sexual dysfunction, somatic metabolic disorder and the like, and seriously affecting life quality. At present, testosterone replacement therapy is mainly used clinically, endogenous testosterone synthesis can be rapidly improved, but side effects such as prostatic hyperplasia and liver injury are caused, and partial patients are forbidden, and most of the existing non-hormonal conditioning means are auxiliary, so that the problems of fuzzy action targets, unstable curative effects and ambiguous mechanism are generally caused, and the clinical safety conditioning requirements are difficult to meet. Steroid synthesis acute regulatory protein (StAR), stAR related lipid transfer domain 7 (StARD 7), cytochrome P450 cholesterol side chain lyase (P450 scc/CYP11A 1) and 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) are key genes for testosterone synthesis of testis Leydig cells, the down regulation of mRNA expression level is an important molecular mechanism for the occurrence and development of male delayed hypogonadism, and the key genes for testosterone synthesis of testis Leydig cells directly regulate and control cholesterol transport and conversion and are key links of testosterone biosynthesis pathways. At present, the correlation of ginsenoside Rg4 and a core key gene synthesized by testosterone of a testicle Leydig cell is not researched, the effect and a molecular mechanism of the ginsenoside Rg4 for improving male delayed hypogonadism by regulating and controlling the transcription level of the core key gene synthesized by testosterone of the testicle Leydig cell are not researched, and the conventional mechanism verification method mostly depends on a complex protein hybridization technology, so that the problems of complicated operation and high cost are solved, and quality control and batch detection in the research and development of subsequent products are not facilitated. In conclusion, the effect and molecular mechanism of the ginsenoside Rg4 for improving the male delayed hypogonadism through regulating the core key gene transcription level of testosterone synthesis of testicle Leydig cells are clear, and the method has important practical significance for realizing non-hormone targeted conditioning of the male delayed hypogonadism. Disclosure of Invention In order to solve the problems of large treatment side effect, fuzzy non-hormonal conditioning effect target, unstable curative effect and undefined mechanism of the existing treatment method for male delayed hypogonadism (LOH), the invention provides the application of ginsenoside Rg4 serving as the only active ingredient in preparing the medicament for improving male delayed hypogonadism. The technical scheme adopted by the invention for solving the technical problems is as follows: the invention provides an application of ginsenoside Rg4 as a unique active ingredient in preparing a medicament for improving male delayed hypogonadism. As a preferred embodiment, the functions of the ginsenoside Rg4 include: (1) Increasing serum total testosterone and free testosterone levels; (2) Inhibiting abnormal elevation of levels of xanthogen and follicle stimulating hormone in serum; (3) Targeting the transcriptional level of a core key gene that regulates testosterone synthesis in testicular Leydig cells; (4) Promote the transportation and transformation of cholesterol; (5) Promoting endogenous testosterone synthesis; (6) The hormone secretion homeostasis of the HPG axis is regulated. As a preferred embodiment, the preparation method of the ginsenoside Rg4 comprises the following steps: (1) Preparing a pediococcus acidilactici TH903 bacterial suspension; Activating Pediococcus acidilactici TH903, inoculating to a liquid MRS culture medium, standing for culture, centrifuging, collecting bacterial precipitate, suspending with sterilized distilled water, and regulating viable count to obtain Pediococcus acidilactici TH903 bacterial suspension; (2) Preparing ginseng berry extract; weighing ginseng berry, adding deionized water, extracting under reflux, filtering, mixing filtrates, and concentrating under reduced pressure to obtain ginseng berry extract; (3) Fermenting and converting; adding glu